Incidentaloma secondary prevention

Incidentaloma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Incidentaloma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Incidentaloma secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Incidentaloma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Incidentaloma secondary prevention
CDC on Incidentaloma secondary prevention
Incidentaloma secondary prevention in the news
Blogs on Incidentaloma secondary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Incidentaloma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

• Effective measures for the secondary prevention of [disease name] include:
• Excess hormone secretion may develop in up to 20% of patients with previously nonfunctional adrenal tumors during follow- up (37, 38, 123).
• The transformation rate of nonfunctional adrenal masses to functional tumors seems to be higher in adrenal masses greater than 3 cm in size (38).

• Annual biochemical follow-up for up to 5 yr may be reasonable for patients with adrenal incidentalomas, especially if the tumor is more than 3 cmin size (20, 21, 37, 45).

• No routine follow-up of adrenal incidentalomas with a non-contrast attenuation value no greater than 10 HU.

• A one-time follow-up scan in 6–12 months may be reassuring to the physician and the patient (2, 12, 40, 124).

• Patients with adrenal masses less than 4 cm in size and a non-contrast attenuation value more than 10 HU should have a repeat CT study in 3–6 months and then yearly for 2 yr.

• Surgical excision may be considered for tumors with indeterminate radiological features that grow at least 0.8 cm over 3- to 12-month follow-up (10).